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ABSTRACT
Background/Aims: We evaluated our 16-year single-center experience of pediatric post-transplant lymphoproliferative disorder (PTLD) 
cases who underwent liver transplantation between 2001 and 2017. 
Materials and Methods: Of the 236 pediatric patients who underwent liver transplantation between 2001 and 2017, the clinical and 
laboratory data of eight patients diagnosed with PTLD were reviewed. The pre-transplant Epstein-Barr virus (EBV) status of 172 patients 
was also recorded.
Results: The total incidence of PTLD was 3.4%. The incidence of PTLD was 10% in pre-transplant EBV immunoglobulin G (IgG)-sero-
negative patients and 0.8% in pre-transplant EBV IgG-seropositive patients. The mean age of the patients at liver transplantation was 
2.71±3.21 years, and four patients were aged below 1 year at the time of transplantation. PTLD was diagnosed at 21.81±18.1 months 
after transplantation. The primary site of involvement was variable among patients: peripheral and mediastinal lymph nodes, stomach 
and intestine, transplanted graft, bone marrow, and nasopharynx. The eosinophil count varied greatly among patients, with a mean 
value of 524.62±679/mm3. Three patients had a food allergy and were administered an elimination diet at the time of PTLD diagnosis. 
Six patients had PTLD of B-cell origin. One patient died due to neutropenic sepsis during chemotherapy, whereas seven patients were 
followed up in full remission for 7.75±4 years.
Conclusion: PTLD is a life-threatening complication of solid-organ transplantation with a heterogeneous clinical spectrum. Food allergy 
had a close association with PTLD. A close follow-up of patients with risk factors and an early diagnosis with appropriate treatment may 
lead to a better outcome.
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INTRODUCTION
Post-transplant lymphoproliferative disease (PTLD) is a sig-
nificant complication of pediatric solid-organ transplanta-
tion, with a reported incidence of 6%-20% and a mortality 
rate of 12%-60% (1-3). The development of PTLD is asso-
ciated with discordance between immunosuppression and 
immune reaction. The risk of graft rejection has decreased 
with the use of potent immunosuppressants; however, the 
impairment of T-cell functions can increase the risk for 
PTLD (4). Most pediatric PTLD cases are associated with 
Epstein-Barr virus (EBV) infection, and EBV-related PTLD 
tends to occur in the first 1 to 2 years after transplantation 
(5,6). The disease has a wide clinical spectrum changing 
from polyclonal PTLD to lymphoma (5). In this study, we 
present our 16-year single-center experience of pediatric 
PTLD cases after liver transplantation.
MATERIALS AND METHODS
Of the 236 pediatric patients who underwent liver trans-
plantation between 2001 and 2017, the clinical and lab-
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oratory data of eight patients diagnosed with PTLD were 
reviewed. The patient age, gender, primary diagnosis before 
transplantation, age at transplantation, donor type, and time 
of PTLD emergence after transplantation were recorded.
PTLD was diagnosed when there was a histopathologi-
cal confirmation of the lymph node or the involved organ. 
PTLD was histopathologically classified according to the 
World Health Organization classification into four groups: 
early type, polymorphic, monomorphic PTLD, and classical 
Hodgkin lymphoma. The B- or T-cell origin of the lesions 
was noted. The EBV association was defined according to 
EBV-encoded RNA (EBER) in situ hybridization in tissue 
samples. The EBV viral loads, which were measured by 
real-time polymerase chain reaction (PCR) of EBV DNA 
from peripheral blood, were also recorded. The pre-trans-
plant EBV serology was available for 172 of 236 patients. 
Pediatric patients with negative EBV IgM and IgG levels 
were recorded as EBV-naive. Patients were clinically clas-
sified as early and late PTLD and as early PTLD occurring 
within 1 year after transplantation. The primary site of 
PTLD was also recorded. 
Laboratory values at the time of PTLD diagnosis were in-
vestigated: serum albumin, lactate dehydrogenase (LDH) 
and C-reactive protein (CRP) levels, and eosinophil count, 
and the immunosuppressive drug levels before PTLD di-
agnosis were noted. Upper gastrointestinal endoscopy 
and colonoscopy were performed for patients with gas-
trointestinal symptoms. Postoperative complications like 
rejection, infection, food allergy, or recurrent surgery after 
liver transplantation were evaluated. Patients diagnosed 
with a food allergy were recorded.
All patients, except one, were administered tacrolimus 
for immunosuppression. Our center’s protocol for im-
munosuppression was as follows: 10 mg/kg prednisolone 
was administered in theater, then tapered to 1 mg/kg in 
1 month, and gradually weaned off in 6 months. Myco-
phenolate mofetil was administered to all patients at a 
dose of 20 mg/kg/day for 6 months. Tacrolimus was the 
main immunosuppressive agent, and our study protocol 
targeted trough levels of tacrolimus from 10 to 12 ng/mL 
in the immediate postoperative period, then 6 to 8 ng/mL 
at 1 month after liver transplantation, and 4 to 6 ng/mL at 
1 year after liver transplantation. The treatment for PTLD 
and prognosis after PTLD were also recorded.
Informed consent was obtained from all patients and 
their parents; the study was approved by the Ethics Com-
mittee of Başkent University.
Statistical analysis was performed using Statistical Pack-
age for Social Sciences (SPSS) version 20 (IBM Corp.; Ar-
monk, NY, USA).
RESULTS
Of the 236 pediatric patients who underwent liver trans-
plantation between 2001 and 2017, eight patients were 
diagnosed with PTLD, with an incidence of 3.4%, among 
which six were male. The mean age of the patients at liv-
er transplantation was 2.71±3.21 years (min-max: 0.5-10 
years), and four patients were aged below 1 year at the 
time of transplantation. All patients received a liver trans-
plant from living related donors. Three patients were di-
agnosed with biliary atresia, three patients had progres-
sive familial intrahepatic cholestasis (PFIC), one patient 
had hepatoblastoma, and one patient had cryptogenic 
cirrhosis. PTLD was diagnosed at 21.81±18.1 months af-
ter transplantation (min-max: 4-57 months). Since 2010, 
only two cases have been diagnosed with PTLD. The pri-
mary diagnosis and demographic characteristics of the 
patients are shown in Table 1. 
 The presenting symptoms were cervical lymph node en-
largement in three patients, abdominal pain and diarrhea 
in two patients, cough in one patient, and treatment-re-
sistant nasal stuffiness in one patient. Two patients were 
diagnosed during routine abdominal ultrasonography 
screening. Some patients had multiple symptoms. The 
primary site of involvement was variable among patients: 
two patients had peripheral lymph node involvement; 
two patients had gastrointestinal PTLD; two patients had 
graft PTLD, one of whom also had bone marrow involve-
ment; one patient had a nasopharyngeal tumor; and the 
remaining patient had a mediastinal mass. 
The laboratory values of the patients at the time of 
presentation were as follows: The mean CRP level was 
52.98±32.52 mg/dL (min-max: 0.8-86 mg/dL), and the 
mean albumin level was 2.95±0.75 g/dL (min-max: 2.1-4 
g/dL). Patients with gastrointestinal and peripheral lymph 
node involvements had initial albumin levels <3 g/dL, 
whereas other patients had initial albumin levels >3 g/dL. 
The eosinophil count varied greatly among patients, with 
a mean value of 524.62±679/mm3 (min-max: 22-1800/
mm3), and the highest values occurred in two patients 
with peripheral lymph node involvement and one patient 
with gastrointestinal involvement. Three patients had a 
food allergy and were administered an elimination diet 
around the time of PTLD diagnosis. Patients were diag-
nosed according to the positivity of specific IgEs in blood 
or skin prick test or eosinophilia in the gastrointestinal 
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epithelium and cessation of symptoms after receiving 
the elimination diet. Patient no.2 had a milk protein and 
wheat allergy; patient no.6 had an egg allergy; and patient 
no.8 had multiple food allergies including milk, egg, red 
meat, poultry, wheat, and lentil. 
Tacrolimus levels vary among patients due to patient 
compliance and drug interactions. The highest tacrolim-
us levels occurred in two patients who underwent trans-
plantation in 2006 and one noncompliant patient who 
underwent transplantation in 2014. The mean trough 
level of tacrolimus in our patients was 12.42±6.48 ng/
mL (min-max: 5.1-22 ng/mL). One patient was on siroli-
mus and mycophenolate mofetil treatment at the time of 
PTLD diagnosis, with a trough level of sirolimus as 4.6 ng/
mL. This patient had intractable epilepsy and was intoler-
ant to calcineurin inhibitors.
The pre-transplant EBV status of 236 patients who un-
derwent liver transplantation between 2001 and 2017 
was evaluated; 172 patients had a pre-transplant EBV se-
rology. Fifty-five patients (32%) were reported as EBV-
naïve, whereas 117 (68%) patients were negative for EBV 
IgM and positive for EBV IgG. Seven patients with PTLD 
had a pre-transplant EBV serology. Six patients were 
EBV-naïve before liver transplantation and negative for 
EBV IgM and EBV IgG. One patient with PTLD occurring in 
the graft (liver) was negative for EBV IgM and positive for 
EBV IgG before transplantation. The incidence of PTLD 
among EBV-naive patients was 10% (6 of 55 patients), 
whereas the incidence of PTLD among patients who had 
positive pre-transplant EBV IgG was 0.8% (1 of 117 pa-
tients) (p<0.001).
The EBV PCR status of seven patients at the time of 
PTLD diagnosis was evaluated. Two patients were EBV 
PCR-negative, whereas five patients were EBV PCR-pos-
itive. The mean EBV PCR viral load values were 283, 
900±219, 886 copy/mL (min-max: 11,500-560 000 
copy/mL). The EBV PCR value was unavailable for one 
patient who was serologically EBV-naïve at the time of 
PTLD diagnosis. The laboratory values and PTLD type of 
our patients are given in Table 2.
Immunosuppressive drug doses were tapered in all pa-
tients as a part of the PTLD treatment. Four patients with 
B-cell PTLD were administered intravenous ganciclovir 
for 2 to 3 weeks or oral valganciclovir for 3 months. 
Six patients had lymphoproliferative disease of B-cell 
origin (B-cell PTLD), with a positive CD20 expression on 
lymphocytes. In all of these patients, the EBV viral load 
was high, and EBER was positive at histopathological ex-
amination. Three patients with B-cell disease had been 
accepted in the polyclonal lymphoproliferation phase and 
treated with two to four doses of rituximab. The other 
three patients showed monoclonal proliferation and were 
in the lymphoma phase. In these patients, a modified 
OEPA-C chemotherapy regimen (prednisolone, etopo-
side, vincristine, doxorubicin, and cyclophosphamide) 
for immunosuppressed patients was used in three to six 
courses. Patient no.3 and no. 4 had T-cell PTLD; one was 
in a polyclonal phase and the other was in a monoclonal 
phase. Modified BFM-90 (prednisone, vincristine, dauno-
rubicin, l-asparaginase, cyclophosphamide, cytarabine, 
6-mercaptopurine, and methotrexate) and modified 
OEPA-C regimens were administered to each patient re-
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   Age at  Time of PTLD diagnosis after 
Case No. Primary diagnosis Gender  transplantation (years) Donor liver transplantation (months)
1 Biliary atresia F 0.5 Father 4.5
2 Biliary atresia M 0.75 Mother 11
3 PFIC F 10 Elder sister 39
4 Hepatoblastoma M 3 Grandfather 22
5 Cryptogenic cirrhosis M 4 Mother 4
6 PFIC M 0.8 Uncle 57
7 PFIC M 2.16 Uncle 17
8 Biliary atresia M 0.5 Mother 20
PFIC: progressive familial intrahepatic cholestasis
Table 1. Univariate analysis for risk factors of mortality in cirrhotic patients with UGIB
spectively. Conformal 3D radiotherapy was also admin-
istered to the latter patient who partially responded to 
chemotherapy. 
One patient with B-cell gastrointestinal PTLD devel-
oped an inflammatory myofibroblastic tumor in the lung 
tissue during follow-up and underwent lung surgery. 
The patient who underwent liver transplantation due to 
hepatoblastoma and had polyclonal T-cell disease in his 
mediastinum had died due to neutropenic sepsis during 
chemotherapy in the second month of the PTLD treat-
ment. The other seven patients were followed up in full 
remission for 7.75±4 years (min-max: 1-11.3 years). There 
was no graft loss due to PTLD treatment. The PTLD type, 
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    EBV PCR      Follow-up 
    at the time of Albumin Eosinophil Tacrolimus   period after 
Case Involved PTLD Preoperative PTLD diagnosis level count (%) level PTLD  PTLD 
No. site type EBV status  (copy/mL)  (g/dL)  (/mm3)  (ng/mL) treatment Prognosis  (year)
1 Peripheral  B cell, Naive 440 000 2.3 1380 (14.4%) 14.7 Rituximab (4 doses) Remission 10 
 lymph node monoclonal,       IVIG (2 doses) 
  EBER+      Gancyclovir IV,  
        3 weeks 
2 Stomach  B cell, Naive 560 000 2.42 240 (2.33%) 22 Modified OEPA-C Remission 10.75 
 and  monoclonal,      chemotherapy 
 intestine EBER+       (3 courses) 
        Valgancyclovir, po,  
        3 months 
3 Liver + solid  T cell, EBV IgM-, 150 000 4 22 (0.39%) 4.6 Modified OEPA-C Remission 10.75 
 mass at  polyclonal,  IgG+    (sirolimus level, chemotherapy 
 portal hilus EBER-      ng/mL)  (4 courses) 
        Radiotherapy 
4 Mediastinal  T cell,  Unavailable negative 3.57 50 (1%) 8 BFM-90  Exitus due to 0.16 
 lymph nodes monoclonal,      BFM-90 modified neutropenic 
  EBER      modified chemotherapy sepsis 
  unavailable       
5 Nasopharynx B cell,  Naive Unavailable 3 78 (1.26%) 8.8 Rituximab Remission 6.5 
  monoclonal,       (4 doses) 
  EBER+      Modified OEPA-C  
        chemotherapy  
        (4 courses) 
6 Stomach and  B cell, Naive 11 500 2.4 1800 (34%) 8.6 Rituximab Remission 4 
 intestine  polyclonal,      (2 doses) 
 (colon) EBER+      Gancyclovir IV,  
        2 weeks 
7 Liver +  B cell, Naive negative 3.82 210 (1.49%) 5.1 Modified OEPA-C Remission 11.3 
 bone  monoclonal,      chemotherapy 
 marrow EBER+       (6 courses) 
8 Peripheric  B cell,  Naive 258 000 2.1 417 (12%) 19.8 Rituximab Remission 1 
 lymph  polyclonal,      (3 doses) 
 node EBER+      Gancyclovir IV,  
        3 weeks 
EBV: Epstein-Barr virus; PTLD: post-transplant lymphoproliferative disease; EBV Naive: EBV IgM-, IgG-; EBER: EBV-encoded RNA; Modified OEPA-C: Prednis-
olone, Etoposide, Vincristine, Doxorubicin, Cyclophosphamide; BFM-90 modified: Prednisone, Vincristine, Daunorubicin, L-Asparaginase, Cyclophosphamide, 
Cytarabine, 6-Mercaptopurine, Methotrexate; IV: intravenous; IVIG: intravenous immunoglobulin
Table 2. Laboratory values and post-transplant lymphoproliferative disease (PTLD) type of our patients
treatment, and the prognosis of the patients are shown 
in Table 2. 
Postoperative complications other than PTLD after liver 
transplantation in these seven patients were as follows: 
acute rejection (1), food allergy (3), hepatic artery and 
portal vein thrombosis with bile duct stenosis (1), tacro-
limus-associated cardiac hypertrophy (1), and diaphrag-
matic hernia (1).
DISCUSSION
In our study, the first pediatric PTLD case was experi-
enced in 2005, with a total incidence of PTLD after liv-
er transplantation as 3.4%, which is lower than the in-
cidence of PTLD reported in the literature (1). Six of the 
eight patients with PTLD underwent transplantation be-
fore 2010. We observed a further reduction in PTLD cases 
in subsequent years. A decrease in the incidence of PTLD 
in recent years was also reported by different transplant 
centers (1-3). A preference of lower trough levels of tac-
rolimus in the recent years, full awareness of PTLD signs 
and symptoms, close monitoring of the EBV viral load, 
and adjustment of immunosuppressant blood levels ac-
cordingly may lead to a decrease in the incidence of PTLD 
worldwide and also at our center (1,7). 
In our PTLD case series, three patients had biliary atresia 
and three had PFIC, all of whom (except one) underwent 
liver transplantation at <2.5 years of age confirming that 
younger age at the time of solid-organ transplantation 
is a significant risk factor for PTLD. One of the reasons 
for young age being a risk factor is that most young pa-
tients are EBV-naïve at the time of liver transplantation, 
and they usually receive a graft from an EBV seropositive 
donor (8). Six patients in our PTLD case series were EBV-
naïve at the time of liver transplantation, and these pa-
tients (except one) were aged below 2.5 years.
Older donor age increases the risk of PTLD (1). Because 
liver transplants and partial grafts from living donors were 
used in all of our patients, the donor age was older than 
that for cadaveric transplants, leading to a higher risk of 
EBV-positive donors for younger EBV-naive recipients. 
Approximately 70% to 80% of PTLD cases are EBV-relat-
ed (4,5,8). PTLD related to EBV infection is most common 
within the first 2 years after liver transplantation, and 
non-EBV-related PTLD tends to occur later (6). Similarly, 
in our series, the incidence of PTLD was 10% in pre-trans-
plant EBV-naïve patients and 0.8% in pre-transplant EBV 
seropositive patients. Additionally, most of our patients 
were diagnosed with EBV-driven B-cell PTLD. PTLD of 
T-cell origin (T-cell PTLD) constitutes 10% of the cases 
in the literature (3,9). However, in our series, 25% of pa-
tients had T-cell PTLD, which may be biased due to a low 
patient number.
Hypoalbuminemia and eosinophilia are important labo-
ratory findings that may indicate PTLD (2). In our series 
particularly patients with lymph node and gastrointesti-
nal involvement presented with these features. 
Monitoring the EBV viral loads for early detection of PTLD 
is controversial (1,7,10,11). Some centers experience a 
decrease in the incidence of PTLD after monitoring the 
EBV viral load and reducing immunosuppression upon 
recognition of high-titer EBV of over 10,000 copies/mL 
(7). At our center, we did not perform routine EBV PCR 
screening in EBV-negative patients at the post-trans-
plantation period. Instead of using this technique, we 
preferred observing patients at risk for PTLD such as 
recipient EBV-negative and donor EBV-positive cases, 
young infants, and patients who had clinical and labora-
tory signs indicating the development of PTLD. We hardly 
attempted to avoid very high tacrolimus levels and also 
closely monitored the immunosuppressive drug levels in 
patients and families with drug adjustment and noncom-
pliance problems. 
Extranodal disease is commonly prevalent (75%-80%), 
but solid-organ grafts may also be involved in 15%-30% 
of PTLD cases (1,4). Consistent with the literature, our 
two patients had liver graft involvement at our center. 
Patients with organ involvement required more intense 
treatment compared with those with peripheral lymph 
node involvement. This may be related to early diagno-
sis in nodal disease, as peripheral lymph nodes can be 
easily recognized with physical examination. Symptoms 
like chronic cough or nasal obstruction and difficulty in 
breathing necessitate prompt and early evaluation to 
exclude lymph node enlargement in the mediastinum or 
nasopharynx. Many studies have shown that early diag-
nosis and early intervention with appropriate treatment 
leads to a better outcome (1,7,12). Similarly, Jeong et al. 
(7) have reported that rituximab therapy and reduction 
of immunosuppressive drug treatment were sufficient to 
induce remission in early recognized, localized, and poly-
clonal benign lesions. Nevertheless, in our series, three 
monoclonal B-cell and two T-cell originated cases had re-
ceived chemotherapy and experienced its complications. 
In fact, one patient was lost to follow-up due to death 
because of neutropenic sepsis during the chemotherapy 
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course. As a result, careful examination of patients, close 
follow-up of patients particularly with risk factors, and 
detection of eosinophilia or hypoalbuminemia and incon-
sistent calcineurin drug levels may lead to early diagnosis 
of PTLD and enable us to take some precautions. 
Giraldi et al. (9) applied a risk protocol in which FCD-R 
blocks (fludarabine, cyclophosphamide, doxorubicin, and 
rituximab) were used for polymorphic and non-Burkitt-
like lymphomas, and a BFM-based program was used for 
Burkitt-like lymphomas; they also suggested to include 
rituximab as an initial therapy, decreasing immunosup-
pression together with surgical resection in case of fully 
resectable masses in children. They also recommended 
discontinuation of immunosuppressive drugs together 
with rituximab and chemotherapy in high-risk patients. In 
this study, the disease-free survival was 94% and 75% in 
1 and 5 years, respectively. 
In our study, approximately 50% of patients with PTLD 
could be treated with immunosuppressive drug reduc-
tion and rituximab therapy. In resistant cases, a low-dose 
cyclophosphamide with prednisolone and rituximab may 
result in high response rates. Radiotherapy and a more 
intensive chemotherapy were restricted to patients with 
refractory or recurrent cases. Although ganciclovir does 
not have any inhibitory effect in vivo, it has a theoretical 
advantage on EBV replication, and thus an oral or intra-
venous ganciclovir/acyclovir was administered in more 
than half of our patients. Interestingly, three of eight 
PTLD cases (37.5%) had a food allergy. Food allergies are 
commonly observed in young patients, particularly those 
aged below 3 years after liver transplantation, possibly 
due to immature gastrointestinal and immune systems 
(13-15). Additionally, tacrolimus plays an important role 
in gastrointestinal immunotolerance by increasing the 
intestinal permeability and exposing the body to more 
allergens (16). The incidence of food allergy was 19.2% 
in pediatric patients who underwent liver transplantation 
at our center (unpublished data). Although the incidence 
of food allergy was higher in our patients who received 
liver transplants than in the general population, we ob-
served a further increase in the frequency of food allergy 
in patients with EBV viremia in this study (17). We further 
observed that the incidence of food allergy was high as 
37.5% in PTLD cases. This may be explained by several 
reasons. First, most of our patients with PTLD are aged 
below 3 years, which may lead to a relative increase in 
food allergy. Second, high tacrolimus levels might lead to 
the formation of both PTLD and disturbance in immuno-
tolerance. Third, increased eosinophilia may further sup-
port the coexistence of immune dysregulation and food 
intolerance in patients with PTLD. 
The limitations of our study are due to its retrospec-
tive design and small patient cohort. Further large-scale 
multi-center studies are required for proper investigation 
of the association between PTLD, EBV, and food allergy.
 PTLD is a life-threatening complication of solid-organ 
transplantation with a heterogeneous clinical spectrum. 
Transplant clinicians should be aware of the subtle or 
overt symptoms of this disease and take precautions in 
early phases. A close follow-up of patients with risk fac-
tors and an early diagnosis with appropriate treatment 
may lead to a good outcome. In summary, we emphasized 
the strong association between PTLD and food allergies 
after liver transplantation.
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